文献速递眼底病与葡萄膜炎

增殖性糖尿病视网膜病变失访眼:抗VEGF与全视网膜光凝治疗结局比较

Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
PubMed 文献 · Ophthalmology · 2018-08-02

这项回顾性队列研究比较了增殖性糖尿病视网膜病变(PDR)患者接受抗血管内皮生长因子(VEGF)玻璃体腔注射或全视网膜光凝(PRP)后失访超过6个月的解剖和功能结局。结果显示,抗VEGF组在失访后视力显著恶化,且最终随访时牵拉性视网膜脱离和虹膜新生血管的发生率显著高于PRP组。

要点

  • 抗VEGF组失访后视力从0.43±0.38 logMAR显著恶化至0.97±0.80 logMAR(P=0.001)。
  • PRP组失访后视力暂时恶化,但最终随访时与基线无显著差异(P=0.38)。
  • 最终随访时抗VEGF组牵拉性视网膜脱离和虹膜新生血管发生率显著高于PRP组。

核心结论

  • 接受抗VEGF单药治疗的PDR眼在失访后解剖和功能结局均差于接受PRP治疗的眼。

主要发现

  • 抗VEGF组平均视力从失访前0.43±0.38 logMAR显著恶化至返回时0.97±0.80 logMAR(P=0.001)和最终随访时0.92±0.94 logMAR(P=0.01)。
  • PRP组平均视力从失访前0.42±0.34 logMAR显著恶化至返回时0.62±0.64 logMAR(P=0.03),但最终随访时0.46±0.47 logMAR与基线无显著差异(P=0.38)。
  • 最终随访时抗VEGF组牵拉性视网膜脱离眼数显著多于PRP组(10 vs. 1,P=0.005)。
  • 最终随访时抗VEGF组虹膜新生血管发生率显著高于PRP组(4 vs. 0,P=0.02)。

临床怎么用

  • 对于PDR患者,选择抗VEGF治疗时应充分考虑失访可能带来的不良后果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare anatomic and functional outcomes in eyes with proliferative diabetic retinopathy (PDR) that were lost to follow-up (LTFU) for more than 6 months after treatment with either intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) agents or panretinal photocoagulation (PRP). DESIGN: Retrospective cohort study. PARTICIPANTS: Fifty-nine patients who were LTFU immediately after treatment for more than 6 months between September 2013 and September 2016. METHODS: Patients with eyes receiving either intravitreal anti-VEGF treatment or PRP with the next follow-up visit occurring more than 6 months after treatment were identified. Visual acuity (VA) and anatomic outcomes at the visit before being LTFU, the return visit, the 6-month visit after return, the 12-month visit after return, and the final visit were gathered and compared between the 2 treatment groups. MAIN OUTCOMES MEASURES: Visual acuity and anatomic outcomes. RESULTS: Seventy-six eyes of 59 patients were included in the study, of which 30 received IVI with anti-VEGF and 46 received PRP. In the anti-VEGF group, mean VA worsened significantly when comparing the visit before being LTFU (0.43±0.38 logarithm of the minimum angle of resolution [logMAR]) with the return visit (0.97±0.80 logMAR; P = 0.001) as well as with the final visit (0.92±0.94 logMAR; P = 0.01). In the PRP group, mean VA worsened significantly when comparing the visit before being LTFU (0.42±0.34 logMAR) with the return visit (0.62±0.64 logMAR; P = 0.03). However, no significant difference was observed at the final visit (0.46±0.47 logMAR; P = 0.38). There was a significantly greater number of eyes with tractional retinal detachment in the IVI group compared with the PRP group at the final visit (10 vs. 1, respectively; P = 0.005). There was a significantly greater incidence of neovascularization of the iris in the IVI arm compared with the PRP arm at the final visit (4 vs. 0, respectively; P = 0.02). CONCLUSIONS: Eyes with PDR that received only intravitreal anti-VEGF demonstrated worse anatomic and functional outcomes after being LTFU compared with eyes that received PRP. Given the potential sequelae of being LTFU, the choice of treatment for PDR must be considered carefully.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Obeid A, Su D, Patel SN, et al. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2018. PMID: 30077614. doi:10.1016/j.ophtha.2018.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。